Pharmacological considerations on the use of antiretrovirals in pregnancy

Current Opinion in Infectious Diseases

Volumn 26, Issue 6, 2013, Pages 575-588

  Colbers, Angela ^a   Greupink, Rick ^a   Burger, David ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

antiretroviral; pharmacokinetics; pharmacology; pregnancy

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR PLUS RITONAVIR; INDINAVIR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZIDOVUDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIRTH DEFECT; CONGENITAL MALFORMATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIMB MALFORMATION; LIVER TOXICITY; NONHUMAN; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURITY; PRENATAL DRUG EXPOSURE; RASH; REVIEW; RISK REDUCTION; SECOND TRIMESTER PREGNANCY; SIDE EFFECT; TERATOGENICITY; THIRD TRIMESTER PREGNANCY; VERTICAL TRANSMISSION; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

ANTI-RETROVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84887319532     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000017     Document Type: Review

References (46)

1. US Department of Health &Human Services. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United, States, July DHHS; 2012 31; pp. 1-235. http://aidsinfo.nih.gov/contentfiles/lvguide lines/perinatalgl.pdf. [Accessed 18 June 2013]
2. Taylor GP, Clayden P, Dhar J, et al. British HIV Association guidelines for the management of HIV infection in pregnant women. HIV Med 2012; 13 (Suppl 2):87-157.
3. WHO. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants; recommendations for a public health approach. WHO; 2010; http://www.who.int/hiv/pub/mtct/antiretroviral2010/en/index. html. [Accessed 18 June 2013]
4. Abduljalil K, Furness P, Johnson TN, et al. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet 2012; 51:365-396.
5. Buckoreelall K, Cressey TR, King JR. Pharmacokinetic optimization of antiretroviral therapy in pregnancy. Clin Pharmacokinet 2012; 51:639-659.
6. Rakhmanina NY, Dirajlal-Fargo S, Capparelli EV, Mirochnik M. Pharmacokinetic considerations of perinatal antiretroviral therapy. Curr Drug Metab 2012; 13:744-759.
7. Andany N, Loutfy MR. HIV protease inhibitors in pregnancy: pharmacology and clinical use. Drugs 2013; 73:229-247.
8. Eley T, Bertz R, Hardy H, Burger D. Atazanavir pharmacokinetics, efficacy and safety in pregnancy: a systematic review. Antivir Ther 2013; 18:361-375.
9. Stek AM, Best BM, Luo W, et al. Effect of pregnancy on emtricitabine pharmacokinetics. HIV Med 2012; 13:226-235.
10. Colbers A, Hawkins D, Gingelmaier A, et al. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1 infected pregnant women. AIDS 2013; 13:739-748.
11. Benaboud S, Treluyer JM, Urien S, et al. Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women. Antimicrob Agents Chemother 2012; 56:776-782.
12. Benaboud S, Hirt D, Launay O, et al. Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women. Antimicrob Agents Chemother 2012; 56:857-862.
13. Cressey TR, Stek A, Capparelli E, et al. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr 2012; 59:245-252.
14. Calza L, Manfredi R, Trapani F, et al. Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy. Scand J Infect Dis 2012; 44:381-387.
15. Else LJ, Douglas M, Dickinson L, et al. Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations. Antimicrob Agents Chemother 2012; 56:816-824.
16. Patterson KB, Dumond JB, Prince HA, et al. Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines. J Acquir Immune Defic Syndr 2013; 63:51-58.
17. Fayet-Mello A, Buclin T, Guignard N, et al. Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women. Antivir Ther 2013; 18:171-182.
18. Kreitchmann R, Best BM, Wang J, et al. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy. J Acquir Immune Defic Syndr 2013; 63:59-66.
19. Cespedes MS, Castor D, Ford SL, et al. Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy. J Acquir Immune Defic Syndr 2013; 62:550-554.
20. Cressey TR, Best BM, Achalapong J, et al. Reduced indinavir exposure during pregnancy. Br J Clin Pharmacol 2013; 76 (3):475-483.
21. Fang A, Valluri SR, O'Sullivan MJ, et al. Safety and pharmacokinetics of nelfinavir during the second and third trimesters of pregnancy and postpartum. HIV Clin Trials 2012; 13:46-59.
22. Zorrilla C, Wright R, Osiyemi O, et al. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100mg administered twice daily. HIV Med 2013; doi: 10.1111/hiv.12047. [Epub ahead of print]
23. Colbers A, Best B, Stek A, et al. A comparison of the pharmacokinetics of maraviroc during pregnancy and postpartum [abstract] 20th Conference on Retroviruses and Opportunistic Infections; 3-6 March 2013; Atlanta, GA (paper #391).
24. EMA. Reyataz: summary of product, characteristics. EMA; 2012; http://www. ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Informa tion/human/000494/WC500056380.pdf. [Accessed 18 June 2013]
25. Calcagno A, Trentini L, Marinaro L, et al. Transplacental passage of etravirine and maraviroc in a multidrug-experienced HIV-infected woman failing on darunavir-based HAART in late pregnancy. J Antimicrob Chemother 2013; 68:1938-1939.
26. Croci L, Trezzi M, Allegri MP, et al. Pharmacokinetic and safety of raltegravir in pregnancy. Eur J Clin Pharmacol 2012; 68:1231-1232.
27. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). Antivir Ther 2011; 16:1139-1147.
28. van Hoog S, Boer K, Nellen J, et al. Transplacental passage of nevirapine, nelfinavir and lopinavir. Neth J Med 2012; 70:102-103.
29. Staud F, Cerveny L, Ceckova M. Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure. J Drug Target 2012; 20:736-763.
30. Olagunju A, Owen A, Cressey TR. Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. Pharmacogenomics 2012; 13:1501-1522.
31. Sibiude J, Warszawski J, Tubiana R, et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis 2012; 54:1348-1360.
32. Thorne C, Townsend CL. A new piece in the puzzle of antiretroviral therapy in pregnancy and preterm delivery risk. Clin Infect Dis 2012; 54:1361-1363.
33. Watts DH, Mofenson LM. Antiretrovirals in pregnancy: a note of caution. J Infect Dis 2012; 206:1639-1641.
34. Aaron E, Bonacquisti A, Mathew L, et al. Small-for-gestational-age births in pregnant women with HIV, due to severity of HIV disease, not antiretroviral therapy. Infect Dis Obstet Gynecol 2012; 2012:135030.
35. Floridia M, Mastroiacovo P, Tamburrini E, et al. Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011. BJOG 2013; doi:10.1111/1471-0528.12285
36. Gibb DM, Kizito H, Russell EC, et al. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med 2012; 9:e1001217.
37. Mora S, Giacomet V, Vigano A, et al. Exposure to antiretroviral agents during pregnancy does not alter bone status in infants. Bone 2012; 50:255-258.
38. Siberry GK, Williams PL, Mendez H, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS 2012; 26:1151-1159.
39. Ford N, Calmy A, Andrieux-Meyer I, et al. Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis. AIDS 2013; 27:1135-1143.
40. Shanske AL. Bilateral oblique facial clefts and extremity anomaly in an infant after intrauterine efavirenz exposure and review of its teratogenic risk. AIDS 2012; 26:1775-1779.
41. Esker S, Albano J, Uy J, et al. Monitoring the risk of birth defects associated with atazanavir exposure in pregnancy. AIDS Patient Care STDS 2012; 26:307-311.
42. Westling K, Pettersson K, Kaldma A, Naver L. Rapid decline in HIV viral load when introducing raltegravir-containing antiretroviral treatment late in pregnancy. AIDS Patient Care STDS 2012; 26:714-717.
43. Hegazi A, Hay P. HIV seroconversion in the third trimester of pregnancy: using raltegravir to prevent mother-to-child transmission. Int J STD AIDS 2013; doi:10.1258/ijsa.2012.012121
44. Nobrega I, Travassos AG, Haguihara T, et al. Use of raltegravir in latepresenting, HIV-infected pregnant women. AIDS Res Hum Retroviruses2013; doi:10.1089/AID.2013.0059
45. Renet S, Closon A, Brochet MS, et al. Increase in transaminase levels following the use of raltegravir in a woman with a high HIV viral load at 35 weeks of pregnancy. J Obstet Gynaecol Can 2013; 35:68-72.
46. Cha A, Shaikh R, Williams S, Berkowitz LL. Rapid reduction in HIV viral load in late pregnancy with raltegravir: a case report. J Int Assoc Provid AIDS Car 2013; doi10.1177/2325957413488176